Roivant Sciences Ltd. Common Shares (ROIV) Earnings

Roivant Sciences Ltd. Common Shares

ROIV · Nasdaq

Symbol: ROIV
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Country: Europe
Exchange: Nasdaq

Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes LISRAYA (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies.

Key Issues

Bullish view

The reported Phase 2 results beat key endpoints, and Seeking Alpha said the stock rose 19% on the data. Supporters argue that successful clinical evidence can create substantial value before revenue is visible.

Bearish view

The evidence does not establish regulatory approval, commercial launch timing, or eventual efficacy beyond the reported trial endpoints. Investors may therefore be capitalizing uncertain clinical data before the asset generates sales.

Analyst Consensus

See all

Buy

12 analysts

$35

Current

—

Low

$48

Average

—

High

Average target implies +38.33% versus the current price.

Earnings History

BeatMissNo estimate

Sep 2026upcoming

Next quarter

Reports Nov 9, 2026.

Consensus is -$0.52 EPS for Sep 2026 across 1 estimates, ranging -$0.52 to -$0.52.

ROIV Jun 2026

Reported Aug 6, 2026

: 0.00%
: +3.47%

: -$0.45
: -$0.45
: —
: $1.44M

Reported results

: $1.44M; from $2.17M
: -$365.99M; from -$284.92M
: -25380.93%; from -13130.05%
: -$189.84M; from -$223.35M
: -$0.26; from -$0.33

Highlights

Pipeline catalysts: Roivant remains on track to launch brepocitinib in dermatomyositis by the end of September 2026, with topline data expected in the second half of 2026 for brepocitinib in non-infectious uveitis, IMVT-1402 in cutaneous lupus and mosliciguat in PH-ILD.
Brepocitinib expansion: Priovant enrolled the first patients in a roughly 140-patient Phase 3 cutaneous sarcoidosis study; the prior Phase 2 showed a 77% response rate at Week 16 for 45mg brepocitinib versus 0% for placebo.
Moderna settlement: Genevant and Arbutus received $950 million from Moderna in July, including $771.6 million allocated to Genevant; up to an additional $1.3 billion remains contingent on a favorable resolution of Moderna’s Section 1498 appeal.
Liquidity: Cash, cash equivalents, restricted cash and marketable securities totaled $3.9 billion at June 30, excluding the July Moderna payment; cash and marketable securities alone were $3.8 billion.
Quarterly result: Revenue was $1.4 million, down from $2.2 million a year ago and $2.0 million in the prior reported quarter, while operating loss widened to $366.0 million from $284.9 million and $339.2 million, respectively.
Adjusted spending: R&D expense rose 32% year over year to $202.0 million, led by a $44.8 million increase in anti-FcRn program costs; G&A increased 24% to $165.5 million, partly because of $22.9 million in Moderna-related employee bonuses.
Net loss and expectations: The supplied earnings data show EPS of -$0.45, in line with the -$0.45 consensus; the GAAP filing reports diluted loss per share attributable to Roivant of -$0.26, versus -$0.33 a year ago.
Capital allocation: Roivant repurchased 7.3 million shares for $208.7 million during the quarter, leaving approximately $681.7 million under the buyback authorization.

Analysis

Roivant’s June 2026 quarter was a development-and-commercial-preparation period rather than a revenue quarter. The supplied earnings data show EPS of -$0.45, exactly matching the -$0.45 consensus. In the company’s GAAP filing, however, diluted loss per share attributable to Roivant was -$0.26, compared with -$0.33 in the year-ago quarter. Revenue fell to $1.4 million from $2.2 million a year ago and $2.0 million in the prior reported quarter, while operating loss expanded to $366.0 million from $284.9 million and $339.2 million. Attributable net loss improved to $189.8 million from $223.4 million a year ago and $265.9 million in the prior reported quarter, helped by investment gains and lower losses allocated to noncontrolling interests.

The quarter’s defining feature was the approaching catalyst slate. Roivant is preparing for a potential brepocitinib launch in dermatomyositis by the end of September and began a Phase 3 cutaneous sarcoidosis trial, while multiple Phase 2 and Phase 3 readouts remain scheduled for the second half of 2026. Spending is accelerating accordingly: R&D increased $49.1 million year over year to $202.0 million, and operating cash use reached $270.5 million. The July receipt of $771.6 million from Moderna materially strengthens an already substantial balance sheet, although a further $1.3 billion remains contingent on litigation outcomes.

Brepocitinib launch preparation

Priovant is moving brepocitinib from development toward commercialization while expanding the program into additional dermatology indications. Roivant said preparations for a dermatomyositis launch remain on track for the end of September 2026, pending the FDA decision expected in the third quarter.

Cutaneous sarcoidosis: The first patients entered the Phase 3 BEACON+ study, which plans to enroll approximately 140 patients at roughly 70 sites. The trial will randomize patients 3:2 between 45mg brepocitinib and placebo, with a Week 16 response endpoint; the preceding Phase 2 produced a 77% response rate versus 0% for placebo.
Other indications: Enrollment in the Phase 2b/3 lichen planopilaris study is progressing, while topline Phase 3 non-infectious uveitis data are expected in the second half of 2026. Cutaneous sarcoidosis topline data are expected in 2028.
Commercial economics: Brepocitinib R&D spending was $14.1 million in the quarter, down from $15.0 million a year earlier, even as commercial-readiness work moved closer to a potential launch.

Pipeline readouts ahead

The near-term pipeline calendar is concentrated across Immunovant and Pulmovant, leaving the second half of calendar 2026 unusually eventful for a company still generating minimal revenue.

IMVT-1402: Immunovant continues to target topline proof-of-concept data in cutaneous lupus erythematosus during the second half of 2026, alongside an update on the difficult-to-treat rheumatoid arthritis program. Potentially registrational programs span Graves’ disease, myasthenia gravis, CIDP, rheumatoid arthritis and Sjögren’s disease.
Mosliciguat: Pulmovant’s Phase 2 study in pulmonary hypertension associated with interstitial lung disease remains on track for topline data in the second half of 2026.
Development intensity: Anti-FcRn program costs increased $44.8 million year over year across endocrine, neurological, rheumatology and dermatology programs, while mosliciguat costs increased $4.7 million.

Moderna settlement proceeds

The Moderna settlement is now producing cash, but its accounting and ultimate value remain tied to the litigation structure. Genevant and Arbutus received the $950 million fixed payment on July 8, after quarter-end. Roivant’s share of Genevant’s allocation was recorded as a $771.6 million receivable at June 30 and received in July.

Contingent consideration: Up to an additional $1.3 billion is payable if Moderna’s Section 1498 appeal is resolved favorably for Genevant and Arbutus. A partial favorable decision could result in a prorated payment, while an adverse outcome could produce no contingent payment.
Pfizer and BioNTech: Genevant and Arbutus filed three international lawsuits in July, covering Canada and 20 European countries through the Unified Patent Court. The U.S. Pfizer litigation remains in discovery.
Quarterly accounting: Roivant recorded only a $0.4 million gain from the settlement in the June quarter, reflecting the final allocation of litigation costs; the substantial cash receipt occurred after the reporting date.

Higher R&D and G&A

The income statement reflected the cost of advancing several late-stage programs and preparing for commercialization. R&D increased $49.1 million, or 32%, to $202.0 million, while G&A rose $31.5 million, or 24%, to $165.5 million.

R&D mix: Program-specific costs rose $49.4 million to $139.1 million. Personnel-related costs added $3.8 million, including $4.1 million of Moderna-related employee bonuses. Non-GAAP R&D was $192.9 million versus $141.0 million a year ago.
G&A mix: The increase was driven largely by $18.8 million of Moderna-related employee bonuses and $6.3 million of employer payroll taxes tied to equity awards. Non-GAAP G&A was $90.7 million versus $62.6 million.
Cash burn: Operating cash use increased to $270.5 million from $204.4 million a year earlier, reflecting higher clinical spending, brepocitinib commercial preparation and increased tax payments.

Liquidity and buybacks

Roivant ended the quarter with substantial liquidity despite continued operating losses and capital returns. Cash, cash equivalents and marketable securities were $3.8 billion at June 30, and the company reported $3.9 billion including restricted cash. The July Moderna receipt is excluded from those balances.

Balance sheet: Cash and cash equivalents were $1.25 billion and marketable securities were $2.59 billion at quarter-end, compared with a combined $4.29 billion at March 31.
Share repurchases: Roivant bought back 7.3 million shares for $208.7 million at an average price of roughly $28.58 per share. Approximately $681.7 million remains available under the program.
Forward funding: Management said existing liquidity supports the cash runway into profitability, although the filing notes that future development, commercialization, licensing and strategic activity could require additional capital.